This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Taking a Look at the Changing Landscape for Spinal Muscular Atrophy After AAN 2019 and Pending FDA Decision On Zolgensma's Approval

Ticker(s): NVS, BIIB, RHHBY

Who's the expert?

Name: Dr Edward Smith - MD

Institution: Duke University 

  • Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke.
  • Treats hundreds of neuromuscular patients, including over 60 Spinal Muscular Atrophy patients and 80 Duchenne MD patients (all ages).
  • Has administered over 250 doses of Spinraza since April 2017.
  • Actively involved in clinical research and trials with a focus on neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.

Interview Questions
Q1.

Questions to come from Adam Feuerstein and Damian Garde of STAT News!

Added By: joe_mccann
Q2.

Three years ago, there were no medicines to treat SMA. Today, there is one (Spinraza) approved, a second (Zolgensma) on the cusp of approval, and a third (risdiplam) not far behind. What has this meant for the SMA community? Where do you see the disease and its therapies evolving from here?

Added By: joe_mccann
Q3.

Characterize advantages, disadvantages of Spinraza. How does real-world use compare to clinical trial data?

Added By: joe_mccann
Q4.

Is Zolgensma a cure? Should the “cure” word be used?

Added By: joe_mccann
Q5.

Can you, should you, compare Zolgensma to Spinraza? How do the respective therapies compare across efficacy, safety, convenience?

Added By: joe_mccann
Q6.

Will SMA patients on Spinraza today switch to Zolgensma? Can you walk through that decision-making process?

Added By: joe_mccann
Q7.

What percentage of your patients do you think might be treated with Zolgensma over the next year? Five years?

Added By: joe_mccann
Q8.

There has been a lot of discussion about the (proposed) high cost of Zolgensma. It's likely to be the most expensive medicine in the world. How do you view the cost benefit of a gene therapy for SMA?

Added By: joe_mccann

Are You Interested In These Questions?



Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.